Core Viewpoint - Inhibitor Therapeutics, Inc. is advancing its pharmacokinetic clinical program for treating basal cell carcinomas in patients with Basal Cell Carcinoma Nevus Syndrome and plans to file a new global patent application for its proprietary itraconazole formulation [1][6]. Group 1: Clinical Development - The comparative pharmacokinetic, safety, and tolerability study is being conducted in healthy adults in Malaysia as a three-way crossover study against a reference drug, in collaboration with Avior Bio, Inc. [2] - The study is progressing through its dosing periods, with Period 2 on April 10, 2026, and Period 3 on April 24, 2026, with top-line results expected before the full Clinical Study Report [3]. - This pharmacokinetic study is anticipated to be the final clinical study required before submitting a New Drug Application to the FDA for the BCCNS program [3]. Group 2: Formulation Strategy - The company employs a proprietary amorphous formulation approach for itraconazole, addressing solubility limitations of the conventional crystalline form, which can lead to variability in absorption [4]. - The Investigational Medicinal Product Dossier supports the formulation strategy, showing the product candidate as amorphous and developed to improve intestinal solubility and absorption [5]. Group 3: Intellectual Property - Inhibitor is preparing a new patent application for its proprietary formulation, which, if granted, would enhance its intellectual property estate and strategic value for the BCCNS program [6]. Group 4: Market Context - Gorlin Syndrome is a rare hereditary disorder leading to multiple basal cell carcinomas, and Inhibitor's itraconazole aims to meet the significant unmet medical need for patients facing repeated surgeries [7]. Group 5: Company Overview - Inhibitor Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies using repurposed, approved active pharmaceutical ingredients, with its lead program targeting surgically eligible basal cell carcinomas in BCCNS [8].

Core Viewpoint - The FDA's swift action against mass compounding practices is seen as a positive development for the industry, emphasizing the importance of patient safety and intellectual property rights [1][3][5]. Company Actions - The company has filed a lawsuit against Hims and Hers for patent infringement related to Semaglutide, despite Hims and Hers scrapping their pill version, indicating a commitment to protecting its intellectual property [4]. - The company emphasizes that compounding should be limited to specific cases rather than mass marketing, highlighting concerns over patient safety and the quality of active pharmaceutical ingredients (APIs) [5][6]. Market Dynamics - The company reported a successful launch of its oral GLP-1 pill, with 246,000 users within five weeks, significantly outperforming previous injectable launches [9][11]. - The initial price of the pill is set at $149, which is considered affordable, and the uptake has been 15 times better than the Wegovy injection launch [11][12]. - The company anticipates a year of pricing headwinds but expects volume growth to provide a tailwind in the future [10]. Manufacturing and Supply Chain - The pill is uniquely manufactured in the U.S. from start to finish, which is uncommon in the industry where many competitors source APIs from abroad [16][17]. Strategic Outlook - The company is actively seeking acquisition opportunities to enhance its R&D capabilities and is open to external innovations that complement its internal developments [18][19]. - Valuations of potential acquisition targets are well understood by the company, which maintains financial discipline in its bidding strategies [21][22]. - The timeline for potential deals is flexible, focusing on finding the right target rather than a specific quantity of deals [23].

Core Viewpoint - Novo Nordisk has filed a lawsuit against Hims & Hers for infringing on its patent related to semaglutide products, claiming that Hims is marketing unapproved compounded versions that pose risks to patient safety [1][7]. Group 1: Legal Action and Patent Infringement - Novo Nordisk is taking legal action to protect its intellectual property and public health by seeking a permanent ban on Hims' sale of unapproved compounded drugs that infringe its patents [7]. - The lawsuit highlights Hims' promotional campaigns that mislead consumers and healthcare professionals regarding the safety and efficacy of its compounded semaglutide products [1][2]. Group 2: Patient Safety Concerns - Compounded semaglutide products marketed by Hims may contain dangerous impurities, with Novo Nordisk's testing revealing impurities of up to 86% in injectable forms and 75% in oral forms, which can lead to severe health risks [2][3]. - The FDA has stated that compounded GLP-1 drugs cannot be verified for quality, safety, or efficacy, raising significant concerns from medical organizations about the risks these knock-off drugs pose to patients [3]. Group 3: Company Initiatives and Market Position - Novo Nordisk emphasizes its commitment to patient safety and has launched educational campaigns to raise awareness about the dangers of unapproved drugs, including initiatives like "Check Before You Inject" [4]. - The company is ensuring that authentic, FDA-approved versions of Wegovy and Ozempic are readily available in the US, thereby discouraging patients from using unapproved alternatives [5].

Core Viewpoint - Ovation Science Inc. has received a new Canadian patent that enhances its market exclusivity and expands its global intellectual property portfolio, supporting long-term revenue growth [1] Group 1: Patent Issuance - The newly issued Canadian patent covers proprietary topical formulations containing CBD and THC [1] - The patent is titled "Composition and method for transdermal delivery of cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC)" [1] - This patent expands Ovation's intellectual property protection beyond its previously issued U.S. patent [1] Group 2: Market Implications - The issuance of the patent significantly strengthens the Company's growing international patent portfolio [1] - The patent enhances the Company's market exclusivity and licensing potential [1]

As filed with the U.S. Securities and Exchange Commission on December 1, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UPEXI, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 5900 83-3378978 (I.R.S. Employer Identification Number) 3030 North Rocky Point ...

Table of Contents As filed with the Securities and Exchange Commission on May 30, 2024 Registration No. 333-279329 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CARMELL CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 001-40228 86-1645738 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer ...

Table of Contents As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CARMELL CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 001-40228 86-1645738 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 2 ...

SAVE FOODS, INC. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. 333-276474 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Nevada 2000 26-4684680 HaPard ...

S-1/A 1 tenx_s1a.htm FORM S-1/A As filed with the U.S. Securities and Exchange Commission on February 1, 2024 Registration No. 333-275856 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tenax Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 26-2593535 (Primary Standard Industrial Classification Code Nu ...